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doi:10.1016/j.jtcvs.2006.10.012bjective: Prediction of surgical site infection and mortality after cardiac surgery
ight allow for interventions to reduce adverse outcomes. We sought to evaluate
xisting risk scores.
ethods: We included 809 consecutive patients undergoing coronary artery bypass
urgery. Data were collected prospectively. Infections were defined as deep sternal
ound infection or mediastinitis by using established criteria and evaluated 60 days
fter surgical intervention. All-cause mortality was assessed at 30 days and 6
onths. We assessed the ability of the National Nosocomial Infections Surveillance
isk index, the EuroSCORE, and the Society of Thoracic Surgeons risk score to
redict infection and mortality. Discrimination was assessed using the area under the
eceiver operating curve.
esults: The rate of surgical site infection was 3.6% (29/809 patients). The National
osocomial Infections Surveillance risk index showed moderate discrimination for
nfection (area under the receiver operating curve of 0.64) and poor ability to stratify
atients into infection risk groups. The EuroSCORE predicted infection and 30-day
nd 6-month mortality with good discrimination (area under the receiver operating
urve of 0.72, 0.78, and 0.77, respectively). Ranking patients by the EuroSCORE
nd dividing the cohort into 3 roughly equal risk groups yielded an ascending risk
or infection of 0.7%, 3.0%, and 7.2%. The preoperative and intraoperative Society
f Thoracic Surgeons risk scores showed good discrimination for surgical site
nfection (area under the receiver operating curve of 0.72 and 0.76, respectively) and
xcellent discrimination for early and late mortality (area under the receiver oper-
ting curve of 0.80). Risk grouping based on the Society of Thoracic Surgeons
core yielded an ascending risk for infection of 0.7%, 3.6%, and 6.4%.
onclusions: The EuroSCORE and the Society of Thoracic Surgeons risk score can
e used for joint risk stratification for surgical site infection and mortality. Both
cores performed better than the National Nosocomial Infections Surveillance risk
ndex.
urgical site infection (SSI) is an infrequent but devastating complication after
cardiac surgery. Deep sternal wound infections and mediastinitis are associ-
ated with increased mortality, repeated surgical procedures, prolonged hos-
ital stay, and increased costs.1-3
Several risk scores for SSI have been developed. The National Nosoc
nfections Surveillance (NNIS) risk index is well accepted for general sur4
owever, it was not adapted specifically for coronary artery bypass graft (CABG)
perations. This score is based on the American Society of Anesthesiologists (ASA)
core, wound class, and operation duration. It does not take into account particular
isk factors among patients undergoing CABG and permits little variability because
ABG operations are always clean and patients’ ASA scores are greater than 2 per
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CDefinition. Fowler and colleagues2 developed a simple bed-
ide risk score using the Society of Thoracic Surgeons
STS) National Cardiac Database, including more than
00,000 patients undergoing CABG surgery. The STS score
redicts the risk for major infections, including SSIs or
epticemia, after CABG. A preoperative score, including
ariables available before surgical intervention and an in-
raoperative score, including preoperative and intraopera-
ive variables, performed well in the validation sample of
he STS database. Finally, the EuroSCORE is a risk score
or 30-day mortality after cardiac surgery that has been well
alidated worldwide.5-8 It has been proposed that t
uroSCORE can predict other adverse outcomes, including
nfections, after surgical intervention.9 The similarity be-
ween risk factors for SSI and mortality might permit joint
isk stratification.
We validated these 3 risk scores in a sample of 809
atients undergoing CABG during 1 year in a single center
n Israel. Our objective was to compare the performance of
hese risk scores and to validate the STS scores of patients
utside the STS database.
aterials and Methods
he study was performed at the Department of Cardiothoracic
urgery at Rabin Medical Center, Beilinson Hospital, a primary-
nd tertiary-care university-affiliated hospital. The hospital be-
ongs to the largest health maintenance organization in Israel
Clalit Health Services), which insures about 60% of its population
more than 3.7 million members of various ethnic origin). The
epartment of thoracic surgery conducts the largest number of
ardiothoracic operations in Israel, including CABG, valve, and
ung operations and cardiac transplantation. A prospective surveil-
ance was performed throughout 2004 (August omitted) by the
nfection control team. Included were all consecutive patients
ndergoing CABG with or without an additional operation. A
edicated infection-control nurse visited the department daily and
ollected data by using a standardized case report form. The
ntibiotic prophylaxis recommended at the time of the study was
ancomycin for valve surgery and cefazolin for all other opera-
ions, both administered as 1 g within 60 minutes before incision.
epeat administration was recommended for cefazolin after dis-
onnection from bypass or after 4 hours. No prophylaxis was
ecommended after surgical intervention.
Preoperative data collected included patient demographics and
Abbreviations and Acronyms
ASA  American Society of Anesthesiologists
CABG coronary artery bypass grafting
NNIS  National Nosocomial Infections Surveillance
ROC  receiver operating characteristic
SSI  surgical site infection
STS  Society of Thoracic Surgeonsetailed data regarding hospital stay and invasive procedures be- d
98 The Journal of Thoracic and Cardiovascular Surgery ● Febrore surgical intervention, preoperative risk factors using
uroSCORE definitions,10 hemoglobin A1c (HBA1c) when ava-
ble, previous antibiotic use, and preoperative patient preparation.
ntraoperative data included the type of operation and procedures
erformed; operation duration; bypass use and duration; hourly
rterial glucose level, continuous temperature for on-pump sur-
ery, and mean intraoperative temperature for off-pump surgery;
iming, dosing, and type of antibiotic prophylaxis; administration
f blood products; and mean fraction of inspired oxygen and PaO2.
ostoperative data included temperature and oxygenation on ar-
ival to the intensive care unit; duration of hypothermia, mechan-
cal ventilation, and intensive care unit stay; complications during
he first 3 postoperative days; and 30-day and 6-month all-cause
ortality. The EuroSCORE and NNIS risk index values were
ollected prospectively. SSIs were diagnosed and classified ac-
ording to Centers for Disease Control and Prevention criter11
Data were obtained from patients’ hospital charts and elec-
ronic databases. The electronic databases available for routine
ork at our hospital present data from all hospitals, primary care
linics, and laboratories belonging to the health maintenance or-
anization. Thus data on background conditions, previous hospi-
alizations, HBA1c, and postdischarge follow-up with hospital or
linic notes, microbiologic studies, and surgical procedures were
vailable. Data for this study were collected as part of the routine
urveillance conducted by the infection control unit at our hospital.
he study was conducted in accordance with the requirements of
he local ethics committee.
The primary outcome assessed was SSI 60 days after surgical
ntervention, including deep sternal wound infection or mediasti-
itis. Because most continuous variables did not have a normal
istribution, the Mann–Whitney U test (nonparametric) was used
or comparisons. For comparisons of dichotomous data, we used
he 2 test. A multiple logistic regression model was constructed to
ssess independent risk factors for SSI. Variables associated with
SI at a P value of less than .1 on univariate analysis were entered
y using stepwise forward logistic regression. We did not include
omposite risk scores in the model because we assessed their
ndividual components.
We assessed the ability of each of the risk scores to predict
ccurrence of the primary outcome and mortality. We used the
rea under the receiver operating characteristic (ROC) curve with
5% confidence intervals to assess the discriminatory ability of
ach of the risk scores. Calibration was assessed by using the
osmer–Lemeshow goodness-of-fit statistic. For each score, we
rouped patients into low-, intermediate-, and high-risk patients to
ssess the ability of the score to identify a clinically meaningful
ercentage of the study population at high risk for infection. All
nalyses were conducted with SPSS 13.0 statistical software
SPSS, Inc).
esults
e evaluated 809 consecutive patients undergoing CABG
hroughout the study period. An operation in addition to
ABG was performed in 121 (15%) patients, most com-
only valve surgery (102 patients). Patient characteristics
re detailed in Table 1. Compared with the STS co
iabetes mellitus was more prevalent in our cohort (phar-
uary 2007
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CDacologically treated diabetes in 330 patients, 41%). The
verage body mass index was lower in our cohort, whereas
ther risk factors, including age, ejection fraction, and re-
eated surgical intervention, were similar. Chronic lung
isease was less frequent but was defined differently. More
perations were performed as emergency operations in our
ohort (89/809 [11%]), whereas other operative character-
stics, including operation duration and valve and on-pump
perations, were similar. Mortality at 30 days was 4.8%
39/809).
The overall rate of SSI was 3.6% (29/809 patients). Ten
34%) infections were diagnosed after discharge, and 3
10%) were diagnosed more than 30 days after surgical
ntervention. Invasive interventions were required for 20
69%) patients. The average length of stay in the hospital
or patients with SSIs was 27.9  19.9 days compared
ith 7.3  7.4 days for patients without SSIs (P  .001).
ix-month all-cause mortality rates were 34.5% (10/29)
ersus 7.6% (59/780), respectively (P  .001). Significant
isk factors for SSI on univariate analysis are detailed in
able 1. Perioperative temperature and oxygenation lev
ere not associated with SSI. Off-pump surgery and iso-
ated CABG were associated with a lower rate of SSI.
ompared with patients undergoing on-pump operations,
ff-pump patients had significantly less combined (18%
114/633] vs 3.4% [6/174], P  .001) and emergency
12.4% [78/631] vs 5.2% [9/174], P  .007) operations.
ancomycin prophylaxis was used in 84.2% (96/114) of
ombined operations versus 4.5% (29/639) of isolated
ABG operations. On multivariate analysis, chronic ob-
tructive pulmonary disease, an operation in addition to
ABG, and diabetes mellitus remained significantly asso-
iated with SSI (Table 2).
NIS Risk Index
e used the ASA score as recorded by the anesthesiologists
reoperatively (data missing for 108 patients) and an oper-
tion duration cutoff of 240 minutes, as defined by the NNIS
ystem for “chest-only” SSIs.4 Nearly all patients wer
lassified as risk index 1 or 2, as expected. The respective
SI rates for these risk groups were 2.0% and 5.8%
Table 3). The discrimination of the score for SSI 
ortality was moderate (Table 4).
uroSCORE
he EuroSCORE was collected prospectively, adhering to
riginal variable definitions. The mean additive and logistic
uroSCORE values in our cohort were 5.18 ( 3.3) and 7.0
 9.0), respectively, which is higher than values reported
rom European cohorts (range, 3.1-4.7).12
Ranking patients by the EuroSCORE and dividing the
ohort into 3 roughly equal groups yielded a high-risk
roup consisting of 33% of patients with an observed rate d
The Journal of Thoracicf SSI of 7.2% (Table 3). The discriminative power o
uroSCORE with regard to prediction of SSI was good
areas under the ROC curve of 0.72 for the additive model
nd 0.73 for the logistic score). Originally modeled to
redict mortality, the EuroSCORE performed well in our
ohort, with an area under the ROC curve of 0.78 for 30-day
ortality and 0.77 for 6-month mortality (Table 4).
TS Risk Score
everal variables in our database were defined differently from
he original variable definitions used in the STS database. We
efined chronic lung disease and diabetes as conditions neces-
itating chronic treatment; myocardial infarction was recorded
ithin 3 months before the operation. We did not collect data
n insertion of an intra-aortic balloon pump.
We ranked our cohort by the STS risk score and divided it
nto 3 risk groups (Table 3). The number of patients 
ach risk group was similar to the distribution observed in the
riginal STS cohort (low risk, 35% vs 31% of patients; inter-
ediate risk, 30% vs 30%; high risk, 35% vs 38% for our
ohort versus the STS database; data supplied by the authors).
he observed rate of infections in the high-risk group was
.4% (mean predicted value for the group, 5.3%). Both the
reoperative and intraoperative (omitting intra-aortic balloon
ump) scores discriminated well between patients with and
ithout SSIs (Table 4). The area under the ROC curve
.72 for the preoperative score and 0.76 for the intraoperative
core, indicating good discrimination. The respective values in
he original STS validation cohort were 0.70 and 0.71. Cali-
ration was assessed against the predicted probability of infec-
ion, as reported in the original model derivation. The Hosmer–
emeshow 2 value was 9.86 (P  .25) for the preoperative
nd 6.55 (P  .5) for the intraoperative scores, indicating
dequate calibration. The score we used was designed to pre-
ict major infections but predicted mortality in our cohort with
xcellent discrimination (areas under the ROC curves of0.80
or both the preoperative and intraoperative models, Table
iscussion
e assessed the ability of several risk indexes to predict
eep sternal wound infections in a prospectively collected
ohort of patients undergoing CABG. Our study shows
ood discriminative power and adequate calibration for the
TS preoperative and intraoperative risk scores. The
uroSCORE, originally designed to predict mortality, pre-
icted SSI with good discrimination. We found that both the
TS score and the EuroSCORE were highly predictive for
hort- and long-term survival after surgical intervention.
erformance of the NNIS risk index for prediction of SSI
as inferior to that of the STS risk score and the
uroSCORE.
The STS risk score was developed by using a national
atabase assessing mainly cardiovascular process and out-
and Cardiovascular Surgery ● Volume 133, Number 2 399
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A
CDABLE 1. Characteristics of patients with and without SSIs*
ariable No SSI (780 patients) SSI (29 patients) P value
emography
Age 65.5 ( 11.0) 69.43 ( 10.1) .05
66.5 (31.1-91.4) 72.1 (46.9-83.7)
Female sex 165 (21.2%) 9 (31.0%) .204
Elective operation† 236 (30.4%) 13 (44.8%) .098
Hospital stay before operation‡ 7d ( 7) 7d ( 7) .381
3d (0-50) 2d (0-27)
reoperative risk factors
BMI§ 27.9 ( 4.8) 28.0 ( 4.6) .898
27.4 (17.2-55.2) 26.8 (21.8-39.0)
Smoker within 30 d of operation 251 (33.7%) 7 (25.9%) .398
COPD 43 (5.5%) 5 (17.2%) .009
Diabetes .004
Oral treatment 231 (30.0%) 13 (44.8%)
Insulin treatment 79 (10.3%) 7 (24.1%)
Chronic renal failure (creatinine 2.2 mg/dL) 18 (2.3%) 1 (3.4%) .691
Moderate-severe left ventricular dysfunction 234 (30.0%) 11 (37.9%) .361
perative information
Adequate antibiotic prophylaxis 414 (54.9%) 12 (42.9%) .209
Administration of prophylaxis 750 (96.2%) 25 (86.2%) .029
Adequate timing before operation 481 (65.7%) 12 (52.2%) .179
Recommended agent used 713 (93.0%) 24 (82.8%) .040
Adequate repeat dose 675 (90.1%) 24 (96.0%) .500
Discontinuation after operation 770 (99.2%) 28 (100%) 1.000
Emergency operation¶ 84 (10.8%) 5 (17.9%) .240
Repeated CABG 40 (5.1%) 3 (10.3%) .220
Operation in addition to CABG 109 (14.0%) 12 (41.4%) .001
Off-pump operation 174 (22.3%) 0 .005
Double thoracic use 576 (73.8%) 22 (75.9%) .808
Blood product administration 448 (61.2%) 23 (88.5%) .005
Operation duration (min) 229.5 ( 83.7) 266.9 ( 59.6) .001
215 (60-1074) 260 (178-461)
lucose control
HBA1c (%)# 8.0 ( 1.8) 8.2 ( 2.0) .858
7.7 (4.9-12.8) 7.4 (6.5-12.0)
Preoperative measurement 140 ( 64) 166 ( 61) .017
119 (42-548) 143 (88-279)
Mean intraoperative 151 ( 38) 171 ( 41) .003
143 (73-357) 164 (96-188)
Mean day 1 postoperatively 185 ( 35) 190 ( 39) .452
179 (109-356) 187 (126-316)
Mean day 2 postoperatively 153 ( 32) 161 ( 32) .227
149 (73-327) 154 (111-244)
ostoperative course
Duration of mechanical ventilation (h:min) 12:02 (4:32) 12:04 (3:53) .760
11:45 (0-23:40) 12:30 (3:00-19:30)
Reopening 32 (4.2%) 1 (4.3%) .975
Infectious complications** 29 (3.8%) 5 (21.7%) .001
Other complications** 27 (3.7%) 1 (4.8%) .801
30-d all-cause mortality 39 (5.0%) 0 .217
60-d all-cause mortality 59 (7.6%) 10 (34.5%) .001
00 The Journal of Thoracic and Cardiovascular Surgery ● February 2007
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CDome measures.2 There were several differences betwe
ur methods and the STS database. Risk factors were col-
ected by using the EuroSCORE definitions.10 The primary
utcome of interest in our study included deep sternal
ound infection and mediastinitis, whereas Fowler and
olleagues2 included superficial site infection and septic-
ia in their primary end point of major infection. Our
urveillance included postdischarge follow-up for SSI, and
ndeed, more than 30% of infections were identified after
ischarge. Thus the absolute number of infections in our
ohorts is not comparable. However, despite these dif-
erences, the model performed very well in our cohort. In
he highest risk group, consisting of one third of the
ohort, the rate of SSI was 6.4% compared with 0.7% in
he low-risk group. An important risk factor for SSI
merging in our cohort was intraoperative glucose con-
rol (Tables 1 and 2), which was not assessed in the
atabase. It should be investigated whether inclusion of
erioperative glucose values might improve the perfor-
ance of the model. Interestingly, the score predicted mor-
ality with excellent discrimination.
The EuroSCORE is a well-validated score for prediction
f mortality after cardiac surgery.6-8 All variables included
n the EuroSCORE were prospectively collected by using
heir original definitions. The score predicted both short-
erm (30-day) and long-term (6-month) mortality rates with
ery good discrimination in our cohort (area under the ROC
urve of 0.78 and 0.77, respectively), somewhat better than
ABLE 1. Continued
ariable No
isk scores
NNIS risk index
Additive EuroSCORE
Logistic EuroSCORE
STS preoperative
STS intraoperative
alues of continuous variables are given as means (standard deviations
nfection; BMI, body mass index; COPD, chronic obstructive pulmonary di
ational Nosocomial Infections Surveillance; STS, Society of Thoracic Sur
or surgical intervention from home. ‡Among patients hospitalized before s
atients with SSIs (83%). Defined as fulfilling all of the variables listed be
0 minutes before incision; use of the recommended antibiotic agent; repe
fter 4 hours for off-pump operations; and discontinuation of prophylaxis
urgeon or before the beginning of the next working day. #Data available f
ithin 3 months before surgical intervention: 113 (36%) of 310 patients wi
ostoperative days. Other complications include acute myocardial infarc
ailure.escribed in an earlier cohort at our center.5 Performance of 9
The Journal of ThoracicS
he EuroSCORE with regard to prediction of SSI has been
ssessed in a single study previously.9 In our dataset th
iscriminative power of the EuroSCORE for SSI was better
area under the ROC curve of 0.72 for SSI in our coh
.57 for deep sternal wound infection9).
The NNIS risk index is widely used for benchmarking
ithin and between centers. We show that this score is less
780 patients) SSI (29 patients) P value
( 0.38) 1.17 ( 0.39) .478
(0-2) 1 (0-2)
( 3.3) 7.4 ( 2.6) .001
(0-18) 8 (3-12)
( 8.9) 11.1 ( 7.89) .001
(1-76) 10 (2-31)
( 4.76) 11.93 ( 3.40) .001
(0-26) 12 (5-18)
( 5.35) 14.59 ( 4.38) .001
(0-33) 15 (7-25)
he first line and medians (ranges) in the second line. SSI, Surgical site
; CABG, coronary artery bypass grafting; HBA1c, Hemoglobin A1c; NNIS,
. *Percentages might not total 100% because of missing data. †Admitted
al intervention. §Data available for 661 patients without SSIs (85%) and 24
dministration of antibiotic prophylaxis; first dose administered within 0 to
e of cefazolin after disconnection from bypass for on-pump operations or
r surgical intervention. ¶Operation performed immediately on referral to
ients with known diabetes, in whom HBA1c measurement was performed
SSIs and 7 (35%) of 20 patients with SSIs. **Complications during first 3
cerebrovascular event, reintubation without reopening, and acute renal
ABLE 2. Multiple logistic regression model for surgical
ite infection (n  793, Wald 2 for the model  295, 1 df,
< .0001; Hosmer–Lemeshow 2  0.818, 4 df, P  .936)
ariable*
Odds
ratio
95% Confidence
interval
P
value
OPD 3.50 1.19-10.27 .023
ff-pump surgery 0 .995
peration in addition to CABG 3.71 1.67-8.24 .001
iabetes mellitus† 3.14 1.38-7.17 .007
OPD, Chronic obstructive pulmonary disease; CABG, coronary artery
ypass grafting. *Variables included in the model: age, diabetes mellitus,
hronic obstructive pulmonary disease, severe congestive heart failure,
lective surgical intervention, administration of antibiotic prophylaxis, off-
ump surgery, and blood product administration. Operation duration and
lucose levels before and during the operation were correlated with an
peration in addition to CABG and diabetes mellitus, respectively, and thus
ere not entered into the model. †Replacing diabetes mellitus with pre-
perative and intraoperative glucose levels resulted in a final model
ncluding the same variables and mean intraoperative glucose level of
reater than 140 mg/dL significantly associated with SSI (odds ratio, 3.32;SSI (
1.12
1
5.1
5
6.82
4
8.58
8
9.82
10
) on t
sease
geons
urgic
low: a
at dos
afte
or pat
thout
tion,5% confidence interval, 1.11-9.92; P  .032).
and Cardiovascular Surgery ● Volume 133, Number 2 401
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A
CDell adapted for SSI after cardiac surgery than the scores
pecifically designed for these operations.
There are limitations and strengths to our study. We used
single-center, small cohort of patients. However, the small
ohort permitted close and detailed surveillance. The elec-
ronic records used in the hospital permitted preadmission
nd postdischarge data collection. Thus the presence or
bsence of an SSI was confirmed at 60 days postoperatively
n all but 2 patients, in whom no SSIs were recorded in our
ospital, but postdischarge follow-up was not available.
ll-cause mortality was ascertained in all patients. We
ncluded only deep and organ space sternum infections in
ur outcome because the diagnosis of these infections is
nequivocal, and these infections are associated with sig-
ificant morbidity and mortality. The small number of out-
omes in our study precluded the assessment of specific
athogens. Optimally, a risk score should be able to predict
nfections that can be prevented, such as those caused by
taphylococcus aureus. Finally, we did not assess the effect
f risk stratification prospectively. Ultimately, risk stratifi-
ation should be used to improve patient outcomes.
Interventions that have been shown to reduce SSIs in-
lude antibiotic prophylaxis,13 surveillance for and decon-
amination of Staphylococcus aureus,14,15 tight periopera-
ive glucose control,16-20 and optimal skin preparation.21 In
ur study vancomycin was used mainly in combined oper-
tions, and the recommended dose of cefazolin for on-pump
perations was 1 g. Both combined and on-pump operations
ABLE 3. Grouping of patients by preoperative risk of infe
Low risk In
Defined* Patients† SSI Defined*
NIS risk index 0 12 (1.8%) 0 1
uroSCORE 0-3 281 (34.7%) 2 (0.7%) 4-6
TS preoperative 0-6 280 (34.6%) 2 (0.7%) 7-10
SI, Surgical site infection; NNIS, National Nosocomial Infections Surveilla
o each of the risk scores. †Number (percentage of all patients). All patients
core; 675 patients were evaluated for the National Nosocomial Infect
nesthesiologists score or operation duration) for 134 patients.
ABLE 4. Discrimination of each of the risk scores assesse
ortality
SSI
NNIS risk index 0.64 (0.53-0.76)
EuroSCORE additive 0.72 (0.64-0.80)
EuroSCORE logistic 0.73 (0.65-0.81)
STS preoperative 0.72 (0.64-0.79)
STS intraoperative 0.76 (0.68-0.83)
alues are presented as the area under the receiver operating characte
ational Nosocomial Infections Surveillance; STS, Society of Thoracic Suere associated with an increased rate of SSI. Previous h
02 The Journal of Thoracic and Cardiovascular Surgery ● Febrtudies have suggested that -lactams might be superior to
lycopeptides for the prevention of SSIs,22 even in location
ith a high prevalence of methicillin-resistant Staphylococ-
us aureus,23 and that the use of 1 g of cefazolin dosing
ight be insufficient for operations with cardiopulmonary
ypass.24 Other interventions, such as management 
hronic obstructive pulmonary disease before admission,
hould be explored. The benefit of surgical intervention
ersus percutaneous coronary intervention, when possible,
an be reconsidered in light of preoperative assessment,25-27
s well as the necessity of concomitant surgical interven-
ion. Although general measures for prevention of infec-
ions acquired during surgical intervention, such as antibi-
tic prophylaxis, apply to all patients, special interventions
an be considered for patients at high risk for SSIs. The 2
cores we validated can be used to define patients at high
isk, candidates for special interventions to reduce SSIs. The
hreshold of predicted SSI used to implement an interven-
ion should be assessed. Intraoperative and postoperative
isk stratification will allow for close monitoring and early
iagnosis of infections among high-risk patients.
In summary, we show that both the STS risk score and
he EuroSCORE can be used to identify SSI risk among
atients undergoing CABG. The similarity of risk factors
llows for joint risk stratification for SSI and mortality.
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